Suppr超能文献

以最佳支持治疗作为口腔鳞状细胞癌初始治疗的回顾性研究

A Retrospective Study of Best Supportive Care as Initial Treatment for Oral Squamous Cell Carcinoma.

作者信息

Saito Yuko, Hirai Hideaki, Kobayashi Ryota, Kasahara Aki, Kiguchi Tetsuo, Sumita Yoshimasa, Uenoyama Atsushi, Tomihara Kei

机构信息

Division of Oral and Maxillofacial Surgery, Faculty of Dentistry and Graduate School of Medical and Dental Sciences, Niigata University, Niigata, JPN.

出版信息

Cureus. 2025 Aug 4;17(8):e89319. doi: 10.7759/cureus.89319. eCollection 2025 Aug.

Abstract

Objective Patients with oral squamous cell carcinoma (OSCC) may choose best supportive care (BSC) as initial treatment over active treatment for several reasons. However, no previous reports have compared the clinical characteristics of OSCC patients opting for BSC as initial treatment with those receiving standard treatment. This study retrospectively analyzed these differences to identify the factors influencing this decision. Materials and methods This retrospective study was conducted at Niigata University Medical and Dental Hospital, using medical records within January 2018-December 2022 (follow-up until June 2023). Among 135 patients with primary OSCC, received BSC (BSC group) and underwent standard treatment according to the disease stage (non-BSC group). Data included demographic and tumor characteristics, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), underlying diseases, neutrophil-lymphocyte ratio (NLR), albumin levels, living situation (with family, in a care facility, or alone), rationale for BSC selection (untreatable due to poor general condition or no desire for treatment), overall survival (OS) rate, and disease-specific survival (DSS) rate. Age, NLR, and albumin levels were assessed using Student's t-test. Stage classification, ECOG-PS, and living situation were analyzed using the chi-square test. OS and DDS were calculated using the Kaplan-Meier method and compared using the log-rank test. Multiple logistic regression analysis identified factors associated with BSC. Results  The BSC group included 11 males and 13 females (mean age: 84 years; range: 47-92). The non-BSC group included 67 males and 44 females (mean age: 67.4 years; range: 31-89). Female predominance was higher in the BSC group (male-female ratio: 1:1.2) than in the non-BSC group (1:0.7). Primary sites were the lower gingiva in the BSC and the tongue in the non-BSC group. The BSC group exhibited higher NLR (p=0.50) and a significantly lower albumin level (p<0.001). Stage classification (I/II vs. III/IV) and ECOG-PS (0-1 vs. 2-4) differed significantly between groups (p<0.001). Cardiovascular disease was the most frequent comorbidity in both groups. Living situation exhibited no significant differences (p=0.99). The cumulative one-year OS rate in the BSC group was 29.8%, compared to 97.2% and 81.5% in the non-BSC group at one and five years, respectively. The cumulative one-year DSS rate in the BSC group was 31.9%, and 97.2% and 82.8% at one and five years in the non-BSC group were p<0.001 for OS and DSS. Age (OR: 1.20, 95% CI: 1.10-1.36; p=0.0008), stage classification (I/II vs. III/IV) (OR: 13.79, 95% CI: 2.34-137.75; p=0.0026), psychiatric disorder (OR: 8.73, 95% CI: 2.34-137.75; p=0.021), albumin level (OR: 0.03, 95% CI: 0.002-0.24; p=0.003) were factors in BSC. Among patients aged ≥75 years, stage classification (I/II vs. III/IV) (OR: 19.08, 95% CI: 2.51-321.07; p=0.0027), albumin level (OR: 0.003, 95% CI: 9.0×10-0.098; p=0.01) remained significant predictors of BSC. Conclusion Patients opting for BSC tended to be older. Stage classification and albumin level were key factors in BSC across all patients, including those aged ≥75 years. Early diagnosis and timely intervention are vital to improve treatment opportunities. Collaborative discussions among patients, families, and healthcare providers are crucial to develop individualized care plans, ensuring that patients receiving BSC can approach end-of-life care with dignity.

摘要

目的 口腔鳞状细胞癌(OSCC)患者可能因多种原因选择最佳支持治疗(BSC)作为初始治疗而非积极治疗。然而,此前尚无报告比较选择BSC作为初始治疗的OSCC患者与接受标准治疗的患者的临床特征。本研究进行回顾性分析以确定影响这一决策的因素。材料与方法 本回顾性研究在新潟大学医学齿科医院开展,使用2018年1月至2022年12月期间的病历(随访至2023年6月)。135例原发性OSCC患者中,接受BSC治疗的患者(BSC组)和根据疾病分期接受标准治疗的患者(非BSC组)。数据包括人口统计学和肿瘤特征、东部肿瘤协作组体能状态(ECOG-PS)、基础疾病、中性粒细胞与淋巴细胞比值(NLR)、白蛋白水平、生活状况(与家人同住、在护理机构或独居)、选择BSC的理由(因全身状况差无法治疗或无治疗意愿)、总生存率(OS)和疾病特异性生存率(DSS)。年龄、NLR和白蛋白水平采用Student's t检验进行评估。分期分类、ECOG-PS和生活状况采用卡方检验进行分析。OS和DDS采用Kaplan-Meier法计算,并使用对数秩检验进行比较。多因素逻辑回归分析确定与BSC相关的因素。结果 BSC组包括11名男性和13名女性(平均年龄:84岁;范围:47 - 92岁)。非BSC组包括67名男性和44名女性(平均年龄:67.4岁;范围:31 - 89岁)。BSC组女性占比高于非BSC组(男女比例:1:1.2对比1:0.7)。BSC组的原发部位为下牙龈,非BSC组为舌部。BSC组NLR较高(p = 0.50),白蛋白水平显著较低(p < 0.001)。两组间分期分类(I/II期对比III/IV期)和ECOG-PS(0 - 1对比2 - 4)差异显著(p < 0.001)。心血管疾病是两组中最常见的合并症。生活状况无显著差异(p = 0.99)。BSC组的1年累积OS率为29.8%,非BSC组1年和5年的累积OS率分别为97.2%和81.5%。BSC组的1年累积DSS率为31.9%,非BSC组1年和5年的累积DSS率分别为97.2%和82.8%,OS和DSS的p均< 0.001。年龄(OR:1.20,95% CI:1.10 - 1.36;p = 0.0008)、分期分类(I/II期对比III/IV期)(OR:13.79,95% CI:2.34 - 137.75;p = 0.0026)、精神障碍(OR:8.73,95% CI:2.34 - 137.75;p = 0.021)、白蛋白水平(OR:0.03,95% CI:0.002 - 0.24;p = 0.003)是BSC的相关因素。在年龄≥75岁的患者中,分期分类(I/II期对比III/IV期)(OR:19.08,95% CI:2.51 - 321.07;p = 0.0027)、白蛋白水平(OR:0.003,95% CI:9.0×1)仍然是BSC的显著预测因素。结论 选择BSC的患者往往年龄较大。分期分类和白蛋白水平是所有患者(包括年龄≥75岁的患者)选择BSC的关键因素。早期诊断和及时干预对于改善治疗机会至关重要。患者、家庭和医疗服务提供者之间的协作讨论对于制定个性化护理计划至关重要,确保接受BSC的患者能够有尊严地接受临终关怀。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2255/12406284/86c0fc97bfcd/cureus-0017-00000089319-i01.jpg

相似文献

1
A Retrospective Study of Best Supportive Care as Initial Treatment for Oral Squamous Cell Carcinoma.
Cureus. 2025 Aug 4;17(8):e89319. doi: 10.7759/cureus.89319. eCollection 2025 Aug.
5
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
6
The Black Book of Psychotropic Dosing and Monitoring.
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.

本文引用的文献

2
Role of Hematological Markers in Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma.
Indian J Otolaryngol Head Neck Surg. 2023 Sep;75(3):2054-2062. doi: 10.1007/s12070-023-03803-4. Epub 2023 Apr 26.
3
Shared Decision Making in the Care of Patients With Cancer.
Am Soc Clin Oncol Educ Book. 2023 Jun;43:e389516. doi: 10.1200/EDBK_389516.
5
Neutrophil: Lymphocyte ratio and oral squamous cell carcinoma: A preliminary study.
J Oral Maxillofac Pathol. 2019 Jan-Apr;23(1):78-81. doi: 10.4103/jomfp.JOMFP_160_17.
6
Shared decision making in mild cognitive impairment.
Neurol Clin Pract. 2019 Apr;9(2):160-164. doi: 10.1212/CPJ.0000000000000576.
8
Integration of oncology and palliative care: a Lancet Oncology Commission.
Lancet Oncol. 2018 Nov;19(11):e588-e653. doi: 10.1016/S1470-2045(18)30415-7. Epub 2018 Oct 18.
9
Untreated oral cavity cancer: Long-term survival and factors associated with treatment refusal.
Laryngoscope. 2018 Mar;128(3):664-669. doi: 10.1002/lary.26809. Epub 2017 Sep 2.
10
Preoperative Neutrophil-to-Lymphocyte Ratio Predicts the Prognosis of Oral Squamous Cell Carcinoma: A Large-Sample Prospective Study.
J Oral Maxillofac Surg. 2017 Jun;75(6):1275-1282. doi: 10.1016/j.joms.2016.11.022. Epub 2016 Dec 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验